Inside the Peptide Alliance Directory: How 306 Verified Suppliers Map the Industry's Six Segments
The Data Backbone
Every market-size projection and industry trend in The State of Peptides 2026 traces back to the same proprietary source: The Peptide Alliance directory. As of July 2026, it contains 306 active verified suppliers (336 total listings) — each representing a live row in the directory, each manually verified for legitimacy, each tagged by segment, geography, and service line.
No estimate, no "industry contacts suggest." Six hundred suppliers is not a data set; 306 is. And the segment breakdown reveals where the peptide market is actually growing — and where it's reinventing itself.
The Six-Segment Breakdown
The directory divides the supply chain into six segments:
Clinics lead at 121 listings — the largest segment and among the fastest-growing. This reflects a deliberate shift toward physician-supervised peptide programs, driven in part by patients transitioning off compounded GLP-1 products as shortages resolved. More clinical oversight is entering the market, and that's a net positive for safety and legitimacy.
Peptide brands sit at 58 listings, up sharply from earlier counts. The growth here is twofold: new entrants launching next-generation-agonist and research-peptide brands, plus expanded directory coverage into vendors previously flying under the radar. The brand segment is fragmenting — some serve research buyers, some telehealth, some wholesale — but all reflect the same trend: peptides are becoming product lines, not gray-market exceptions.
Compounding pharmacies number 47. Contrary to headlines predicting an exodus after the semaglutide-shortage window closed, most are adapting, not exiting. Many have shifted to hormone-replacement and men's-health peptide lines, or partnered with telehealth platforms for branded fulfillment. The role is changing — from GLP-1 gap-filler to specialized peptide compounder — but the segment remains structurally important.
Research labs (38), manufacturers (23), and wholesale suppliers (19) round out the directory. These segments serve institutional and B2B buyers — clinics sourcing bulk vials, brands white-labeling formulations, labs conducting third-party testing. They're smaller by count but foundational to the entire supply chain.
Geography and the GLP-1 Implicit Segment
Geographic concentration mirrors population and regulatory density: California, Florida, Texas, and Ontario lead, with meaningful clusters in New York and British Columbia. The directory currently spans the US and Canada — global expansion is planned for the H2 edition.
One segment isn't formally broken out yet but defines the entire landscape: GLP-1 as its own line of business. Across clinics, telehealth, and pharmacies, semaglutide and tirzepatide programs are now large enough to track independently. The H2 report will formalize this, but the July data already shows it: GLP-1 is not just the dominant peptide — it's becoming its own vertical within the peptide vertical.
Why Live Data Matters
The directory isn't static. Suppliers enter, exit, merge, lose licenses, get flagged by users. The 306-supplier count reflects the market right now — verified, contactable, categorized. That real-time signal is what allows The Peptide Alliance to publish industry-wide stats with confidence: every claim about supplier density, segment growth, or geographic trends is drawn from rows you can click through and verify yourself.
As the peptide market professionalizes, the gap between "someone told me there are X suppliers" and "here are 306 verified rows" will only widen. The directory is the difference between market gossip and market intelligence.
For the full segment dynamics, geographic heatmaps, and comparative growth analysis, read the complete breakdown in The State of Peptides 2026. For direct access to the verified supplier listings behind these numbers, explore the directory.
This content is for educational purposes only and is not medical advice. Always consult a licensed healthcare provider before starting any peptide protocol.